Prognostic Nutritional Index and Clinical Response in Locally Advanced Cervical Cancer

Gangopadhyay, Aparna

doi:10.1080/01635581.2020.1729820

Cited by 18 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low serum albumin levels were associated with a low nutritional index and predicted a poor prognosis in a cohort of 131 cervical cancer patients treated with RT or CRT [53]. The negative impact of a low nutritional index was further confirmed in a larger and more recent study [54]. Sarcopenia resulting from malnutrition, however, does not affect survival before initiation of treatment, whereas significant loss of skeletal muscle during CRT is associated with an impaired outcome [55][56][57].…”

Section: Hematological Parametersmentioning

confidence: 83%

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Fleischmann

Chatzikonstantinou

Fokas

et al. 2021

Cancers

View full text Add to dashboard Cite

Uterine cervical cancer is one of the leading causes of cancer-related mortality in women worldwide. Each year, over half a million new cases are estimated, resulting in more than 300,000 deaths. While less-invasive, fertility-preserving surgical procedures can be offered to women in early stages, treatment for locally advanced disease may include radical hysterectomy, primary chemoradiotherapy (CRT) or a combination of these modalities. Concurrent platinum-based chemoradiotherapy regimens remain the first-line treatments for locally advanced cervical cancer. Despite achievements such as the introduction of angiogenesis inhibitors, and more recently immunotherapies, the overall survival of women with persistent, recurrent or metastatic disease has not been extended significantly in the last decades. Furthermore, a broad spectrum of molecular markers to predict therapy response and survival and to identify patients with high- and low-risk constellations is missing. Implementation of these markers, however, may help to further improve treatment and to develop new targeted therapies. This review aims to provide comprehensive insights into the complex mechanisms of cervical cancer pathogenesis within the context of molecular markers for predicting treatment response and prognosis.

show abstract

Section: Hematological Parametersmentioning

confidence: 83%

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Fleischmann

Chatzikonstantinou

Fokas

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Focusing on the host factors, high serum CRP levels, low serum albumin levels, high CAR, high ANC, and high NLR were significant risk factors for poor OS in the univariate analyses (Table 2). In addition to CAR and NLR, several other inflammation‐based markers, such as monocyte‐to‐lymphocyte ratio (MLR), platelet‐to‐lymphocyte ratio (PLR), and prognostic nutritional index (PNI), have been regarded as prognostic markers of cervical cancer 31–33 . All of them can reflect systemic inflammation as well as radiation‐induced lymphopenia.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to CAR and NLR, several other inflammation-based markers, such as monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI), have been regarded as prognostic markers of cervical cancer. [31][32][33] All of them can reflect systemic inflammation as well as radiation-induced lymphopenia. Therefore, we next evaluated the association between such inflammatory markers and OS after recurrence.…”

Section: Identification Of Prognostic Factors For Recurrent Cervical Cancer Patientsmentioning

confidence: 99%

High neutrophil‐to‐lymphocyte ratio is a predictor of short‐term survival for patients with recurrent cervical cancer after radiation‐based therapy

Taguchi

Nakajima

Furusawa

et al. 2021

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Patients with recurrent cervical cancer after radiotherapy have poor prognoses because of the lack of effective treatment options. Biomarkers to predict survival outcomes for recurrent cervical cancer are warranted because patients with limited life expectancy sometimes benefit from less aggressive treatment in combination with early palliative care. Therefore, we aimed to explore a predictive biomarker for the outcomes of patients with recurrent cervical cancer. Methods We retrospectively investigated 231 patients initially treated with radiation‐based therapy between January 2004 and December 2015. The associations between clinicopathological features at the time of relapse and overall survival after relapse were assessed. As factors which reflect patients' conditions, we particularly focused on C‐reactive protein‐to‐albumin ratio (CAR) and neutrophil‐to‐lymphocyte ratio (NLR) at the time of relapse. Additionally, we investigated biomarkers predictive of short‐term survival. Results Among 231 patients, 91 patients experienced relapse and 74 patients died during the follow‐up period. Multivariate analysis revealed that treatment after relapse, CAR, and NLR was significantly associated with overall survival. Among them, treatment after relapse significantly affected survival outcomes, and patients who received definitive local treatment had a better 3‐year survival rate than those who received other treatments. Conversely, NLR was the most influential biomarker for short‐term survival, and the prognosis of patients with high NLRs was much worse than those with low NLRs. Conclusions This study thus demonstrated that, for the patients with recurrent cervical cancer who received radiation‐based therapy, definitive local treatment can provide long‐term survival and extremely high NLRs are predictive of short‐term survival.

show abstract

“…The nutritional and immunological status of patients was reported to be associated with cancer invasion, treatment tolerability, cancer progression and prognosis. 19 – 21 Previous studies have devised some systems to evaluate nutritional status and/or immune status and demonstrated their efficiency in predicting the prognosis of cancer patients. 19 , 21 – 23 As a recently emerging scoring system of nutritional status, the controlling nutritional status (CONUT) score was composed of serum albumin levels, total cholesterol levels, and total peripheral lymphocyte counts 24 and was demonstrated to be a predictive or prognostic factor in malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

A Novel Risk Factor for Para-Aortic Lymph Node Recurrence After Definite Pelvic Radiotherapy in Stage IIIB Cervical Cancer

Zhang

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Studies determining which patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB disease benefit from prophylactic extended-field irradiation (EFRT), which can reduce para-aortic lymph node (PALN) failure rates, are limited. The study was designed to evaluate the value of the controlling nutritional status (CONUT) score as a risk factor for predicting PALN recurrence and identifying potential indications of prophylactic EFRT. Methods: From 2010 to 2015, a retrospective review was conducted among patients with FIGO stage IIIB cervical cancer who were treated with definitive pelvic radiotherapy or concurrent chemoradiotherapy. We analyzed para-aortic lymph node metastasis-free survival (PALNMFS) using Kaplan-Meier curves. Multivariate analyses were performed using Cox regression models. Results: A total of 116 patients with FIGO stage IIIB cervical cancer were included in the study and the median follow-up was 42.2 months (range: 3.5-104.2 months). Multivariate analysis revealed that the CONUT score (HR: 3.141; 95% CI: 2.321-5.436; P < .001) and ≥3 pelvic lymph node metastases (HR: 2.235; 95% CI: 1.428-11.242; P < .001) were independent risk predictors of PALNMFS. Compared with the low CONUT group (score<3), the high CONUT group (score≥3) was associated with a significantly worse 3-year disease-free survival rate (46.9 vs 69.5%, P = .001), a significantly lower 3-year overall survival rate (68.5 vs 79.7%, P = .016) and a significantly lower PALNMFS rate (74.8 vs 96.4%, P < .001). Conclusions: A high CONUT score (score≥3) and ≥3 pelvic metastatic lymph nodes were significant predictors of PALNMFS after pelvic radiation in FIGO stage IIIB cervical cancer patients. Patients with these risk factors might benefit from prophylactic EFRT.

show abstract

Prognostic Nutritional Index and Clinical Response in Locally Advanced Cervical Cancer

Cited by 18 publications

References 26 publications

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer

High neutrophil‐to‐lymphocyte ratio is a predictor of short‐term survival for patients with recurrent cervical cancer after radiation‐based therapy

A Novel Risk Factor for Para-Aortic Lymph Node Recurrence After Definite Pelvic Radiotherapy in Stage IIIB Cervical Cancer

Contact Info

Product

Resources

About